V. Menkin, Studies on the isolation of the factor responsible for tissue injury in inflammation, Science, vol.97, pp.165-172, 1943.

P. B. Beeson, Temperature-elevating effect of a substance obtained from polymorphonuclear leucocytes, J Clin Invest, vol.27, p.524, 1948.

E. Atkins and W. B. Wood, Studies on the pathogenesis of fever. II. Identification of an endogenous pyrogen in the blood stream following the injection of typhoid vaccine, J Exp Med, vol.102, pp.499-516, 1955.

J. M. Dayer, From supernatants to cytokines: a personal view on the early history of IL-1, IL-1Ra, TNF and its inhibitor in rheumatology, Arthritis Res Ther, vol.20, pp.1-6, 2018.

C. A. Dinarello, Interleukin-1, Cytokine Growth Factor Rev, vol.8, pp.253-65, 1997.
URL : https://hal.archives-ouvertes.fr/pasteur-01721887

C. A. Dinarello, IL-1: discoveries, controversies and future directions, Eur J Immunol, vol.40, pp.599-606, 2010.

H. Tsutsui, X. Cai, and S. Hayashi, Interleukin-1 family cytokines in liver diseases, Mediators Inflamm, p.630265, 2015.

C. A. Dinarello, Overview of the IL-1 family in innate inflammation and acquired immunity, Immunol Rev, vol.281, pp.8-27, 2018.

A. Mantovani, C. A. Dinarello, M. Molgora, and C. Garlanda, Interleukin-1 and related cytokines in the regulation of inflammation and immunity, Immunity, vol.50, pp.778-95, 2019.

M. Molgora, E. Bonavita, A. Ponzetta, F. Riva, M. Barbagallo et al., IL-1R8 is a checkpoint in NK cells regulating anti-tumour and anti-viral activity, Nature, vol.551, pp.110-114, 2017.

M. Molgora, D. Supino, A. Mantovani, and C. Garlanda, Tuning inflammation and immunity by the negative regulators IL-1R2 and IL-1R8, Immunol Rev, vol.281, pp.233-280, 2018.

C. Moussion, N. Ortega, and J. P. Girard, The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel 'alarmin'?, PLoS ONE, vol.3, pp.1-8, 2008.

C. Cayrol and J. Girard, Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family, Immunol Rev, vol.281, pp.154-68, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02363721

G. Bandara, M. A. Beaven, A. Olivera, A. M. Gilfillan, and D. D. Metcalfe, Activated mast cells synthesize and release soluble ST2-a decoy receptor for IL-33, Eur J Immunol, vol.45, pp.3034-3078, 2015.

H. Hayakawa, M. Hayakawa, A. Kume, and S. Tominaga, Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation, J Biol Chem, vol.282, pp.26369-80, 2007.

S. Sanada, D. Hakuno, L. J. Higgins, E. R. Schreiter, A. Mckenzie et al., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system, J Clin Invest, vol.117, pp.1538-1587, 2007.

J. Bessa, C. A. Meyer, M. C. De-vera-mudry, S. Schlicht, S. H. Smith et al., Altered subcellular localization of IL-33 leads to non-resolving lethal inflammation, J Autoimmun, vol.55, pp.33-41, 2014.

I. Cohen, P. Rider, Y. Carmi, A. Braiman, S. Dotan et al., Differential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammation, Proc Natl Acad Sci, vol.107, pp.2574-2583, 2010.

S. Bekkering, R. Arts, B. Novakovic, I. Kourtzelis, C. Van-der-heijden et al., Metabolic induction of trained immunity through the mevalonate pathway, Cell, vol.172, pp.135-181, 2018.

I. Mitroulis, K. Ruppova, B. Wang, L. Chen, M. Grzybek et al., Modulation of myelopoiesis progenitors is an integral component of trained immunity, Cell, vol.172, pp.147-61, 2018.

S. Moorlag, R. J. Röring, L. Joosten, and M. G. Netea, The role of the interleukin-1 family in trained immunity, Immunol Rev, vol.281, pp.28-39, 2018.

J. Dupaul-chicoine, A. Arabzadeh, M. Dagenais, T. Douglas, C. Champagne et al., The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity, Immunity, vol.43, pp.751-63, 2015.

N. M. Adams, T. E. O'sullivan, C. D. Geary, J. M. Karo, R. A. Amezquita et al., NK cell responses redefine immunological memory, J Immunol, vol.197, pp.2963-70, 2016.

S. Madera and J. C. Sun, Cutting edge: stage-specific requirement of IL-18 for antiviral NK cell expansion, J Immunol, vol.194, pp.1408-1420, 2015.

T. Nabekura, J. Girard, and L. L. Lanier, IL-33 receptor ST2 amplifies the expansion of NK cells and enhances host defense during mouse cytomegalovirus infection, J Immunol, vol.194, pp.5948-52, 2015.

R. Romee, S. E. Schneider, J. W. Leong, J. M. Chase, C. R. Keppel et al., Cytokine activation induces human memory-like NK cells, Blood, vol.120, pp.4751-60, 2012.

X. Huang, L. D. Hazlett, W. Du, and R. P. Barrett, SIGIRR promotes resistance against Pseudomonas aeruginosa keratitis by down-regulating type-1 immunity and IL-1R1 and TLR4 signaling, J Immunol, vol.177, pp.548-56, 2006.

T. Véliz-rodriguez, F. Moalli, N. Polentarutti, M. Paroni, E. Bonavita et al., Role of Toll interleukin-1 receptor (IL-1R) 8, a negative regulator of IL-1R/Toll-like receptor signaling, in resistance to acute Pseudomonas aeruginosa lung infection, Infect Immun, vol.80, pp.100-109, 2012.

L. F. Campesato, A. Silva, L. Cordeiro, B. R. Correa, F. Navarro et al., High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity, Oncotarget, vol.8, pp.49470-83, 2017.

M. Bachmann, J. Pfeilschifter, and H. Mühl, A prominent role of interleukin-18 in acetaminophen-induced liver injury advocates its blockage for therapy of hepatic necroinflammation, Front Immunol, vol.9, pp.1-7, 2018.

S. Belkaya, E. Michailidis, C. B. Korol, M. Kabbani, A. Cobat et al., Inherited IL-18BP deficiency in human fulminant viral hepatitis, J Exp Med, vol.216, pp.1777-90, 2019.
URL : https://hal.archives-ouvertes.fr/hal-02359432

C. L. Langrish, Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham et al., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation, J Exp Med, vol.201, pp.233-273, 2005.

K. Mills, L. S. Dungan, S. A. Jones, and J. Harris, The role of inflammasomederived IL-1 in driving IL-17 responses, J Leukoc Biol, vol.93, pp.489-97, 2013.

C. Sutton, C. Brereton, B. Keogh, K. Mills, and E. C. Lavelle, A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis, J Exp Med, vol.203, pp.1685-91, 2006.

C. E. Sutton, S. J. Lalor, C. M. Sweeney, C. F. Brereton, E. C. Lavelle et al., Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity, Immunity, vol.31, pp.331-372, 2009.

N. Arpaia, J. A. Green, B. Moltedo, A. Arvey, S. Hemmers et al., A distinct function of regulatory T cells in tissue protection, Cell, vol.162, pp.1078-89, 2015.

L. A. Monticelli, L. C. Osborne, M. Noti, S. V. Tran, D. Zaiss et al., IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions, Proc Natl Acad Sci, vol.112, pp.10762-10769, 2015.

E. Bourgeois, L. P. Van, M. Samson, S. Diem, A. Barra et al., The pro-Th2 cytokine IL-33 directly interacts with invariant NKT and NK cells to induce IFN-gamma production, Eur J Immunol, vol.39, pp.1046-55, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00676402

M. D. Smithgall, M. R. Comeau, B. Yoon, D. Kaufman, R. Armitage et al., IL-33 amplifies both Th1-and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK cells, Int Immunol, vol.20, pp.1019-1049, 2008.

J. Kearley, J. S. Silver, C. Sanden, Z. Liu, A. A. Berlin et al., Cigarette smoke silences innate lymphoid cell function and facilitates an exacerbated type I interleukin-33-dependent response to infection, Immunity, vol.42, pp.566-79, 2015.

W. V. Bonilla, A. Fröhlich, K. Senn, S. Kallert, M. Fernandez et al., The alarmin interleukin-33 drives protective antiviral CD8+ T cell responses, Science, vol.335, pp.984-993, 2012.

E. A. Bourgeois, A. Levescot, S. Diem, A. Chauvineau, H. Bergès et al., A natural protective function of invariant NKT cells in a mouse model of innate-cell-driven lung inflammation, Eur J Immunol, vol.41, pp.299-305, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00539574

M. Ferhat, A. Robin, S. Giraud, S. Sena, J. Goujon et al., Endogenous IL-33 contributes to kidney ischemia-reperfusion injury as an alarmin, J Am Soc Nephrol, vol.29, pp.1272-88, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01929544

M. H. Ferhat, A. Robin, L. Barbier, A. Thierry, J. Gombert et al., The impact of invariant NKT cells in sterile inflammation: the possible contribution of the alarmin/cytokine IL-33, Front Immunol, vol.9, p.2308, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02509353

A. Thierry, S. Giraud, A. Robin, A. Barra, F. Bridoux et al., The alarmin concept applied to human renal transplantation: evidence for a differential implication of HMGB1 and IL-33, PLoS ONE, vol.9, p.88742, 2014.
URL : https://hal.archives-ouvertes.fr/hal-01928093

V. Sabapathy, M. E. Stremska, S. Mohammad, R. L. Corey, P. R. Sharma et al., Novel immunomodulatory cytokine regulates inflammation, diabetes, and obesity to protect from diabetic nephropathy, Front Pharmacol, vol.10, p.572, 2019.

T. Mahlakõiv, A. Flamar, L. K. Johnston, S. Moriyama, G. G. Putzel et al., Stromal cells maintain immune cell homeostasis in adipose tissue via production of interleukin-33, Sci Immunol, vol.4, p.416, 2019.

R. G. Spallanzani, D. Zemmour, T. Xiao, T. Jayewickreme, C. Li et al., Distinct immunocyte-promoting and adipocyte-generating stromal components coordinate adipose tissue immune and metabolic tenors, Sci Immunol, vol.4, p.3658, 2019.

J. A. Green, N. Arpaia, M. Schizas, A. Dobrin, and A. Y. Rudensky, A nonimmune function of T cells in promoting lung tumor progression, J Exp Med, vol.214, pp.3565-75, 2017.

A. Christ, P. Günther, M. Lauterbach, P. Duewell, D. Biswas et al., Western diet triggers NLRP3-dependent innate immune reprogramming, Cell, vol.172, pp.162-75, 2018.

E. Kaufmann, J. Sanz, J. L. Dunn, N. Khan, L. E. Mendonça et al., BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis, Cell, vol.172, pp.176-90, 2018.

M. I. Arshad, M. Rauch, L. 'helgoualc'h, A. , J. V. Leite-de-moraes et al., NKT cells are required to induce high IL-33 expression in hepatocytes during ConA-induced acute hepatitis, Eur J Immunol, vol.41, pp.2341-2349, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00681990

A. Matsukawa, T. Fukumoto, T. Maeda, S. Ohkawara, and M. Yoshinaga, Detection and characterization of IL-1 receptor antagonist in tissues from healthy rabbits: IL-1 receptor antagonist is probably involved in health, Cytokine, vol.9, pp.307-322, 1997.

C. A. Dinarello, Immunological and inflammatory functions of the interleukin-1 family, Annu Rev Immunol, vol.27, pp.519-50, 2009.

N. Sakai, H. L. Van-sweringen, R. C. Quillin, R. Schuster, J. Blanchard et al., Interleukin-33 is hepatoprotective during liver ischemia/reperfusion in mice, Hepatology, vol.56, pp.1468-78, 2012.

W. Bernal and J. Wendon, Acute liver failure, N Engl J Med, vol.369, pp.2525-2559, 2013.

D. Gotthardt, C. Riediger, K. H. Weiss, J. Encke, P. Schemmer et al., Fulminant hepatic failure: etiology and indications for liver transplantation, Nephrol Dial Transplant, pp.5-8, 2007.

T. Sakurai, G. He, A. Matsuzawa, G. Yu, S. Maeda et al., Hepatocyte necrosis induced by oxidative stress and IL-1? release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis, Cancer Cell, vol.14, pp.156-65, 2008.

C. Chen, H. Kono, D. Golenbock, G. Reed, S. Akira et al., Identification of a key pathway required for the sterile inflammatory response triggered by dying cells, Nat Med, vol.13, pp.851-857, 2007.

M. Sultan, Z. Ben-ari, R. Masoud, O. Pappo, D. Harats et al., Interleukin-1? and interleukin-1? play a central role in the pathogenesis of fulminant hepatic failure in mice, PLoS ONE, vol.12, p.184084, 2017.

C. Gabay, M. F. Smith, D. Eidlen, and W. P. Arend, Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein, J Clin Invest, vol.99, pp.2930-2970, 1997.

H. Tsutsui, N. Kayagaki, K. Kuida, H. Nakano, N. Hayashi et al., Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice, Immunity, vol.11, pp.80111-80120, 1999.

C. Yan, L. Zhou, and Y. Han, Contribution of hepatic stellate cells and matrix metalloproteinase 9 in acute liver failure, Liver Int, vol.28, pp.959-71, 2008.

M. Shinoda, A. W. Tilles, N. Kobayashi, G. Wakabayashi, A. Takayanagi et al., A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats, J Surg Res, vol.137, pp.130-170, 2007.

B. Shakoory, J. A. Carcillo, W. W. Chatham, R. L. Amdur, H. Zhao et al., Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial *, Crit Care Med, vol.44, pp.275-81, 2016.

H. Tsutsui, K. Matsui, N. Kawada, Y. Hyodo, N. Hayashi et al., IL-18 accounts for both TNF-alpha-and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice, J Immunol, vol.159, pp.3961-3968, 1997.

S. Finotto, J. Siebler, M. Hausding, M. Schipp, S. Wirtz et al., Severe hepatic injury in interleukin 18 (IL-18) transgenic mice: a key role for IL-18 in regulating hepatocyte apoptosis in vivo, Gut, vol.53, pp.392-400, 2004.

A. B. Imaeda, A. Watanabe, M. A. Sohail, S. Mahmood, M. Mohamadnejad et al., Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome, J Clin Invest, vol.119, pp.305-319, 2009.

M. M. Antunes, A. M. Araújo, A. B. Diniz, R. Pereira, D. M. Alvarenga et al., IL-33 signalling in liver immune cells enhances druginduced liver injury and inflammation, Inflamm Res, vol.67, pp.77-88, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02126492

P. Scheiermann, M. Bachmann, L. Härdle, T. Pleli, A. Piiper et al., Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury, Sci Rep, vol.5, pp.1-7, 2015.

M. I. Arshad, S. Patrat-delon, C. Piquet-pellorce, L. 'helgoualc'h, A. Rauch et al., Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis, PLoS ONE, vol.8, pp.1-10, 2013.
URL : https://hal.archives-ouvertes.fr/hal-00874120

N. Kamo, B. Ke, A. A. Ghaffari, X. Shen, R. W. Busuttil et al., ASC/caspase-1/IL-1? signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury, Hepatology, vol.58, pp.351-62, 2013.

H. Y. Kim, S. J. Kim, and S. M. Lee, Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion, FEBS J, vol.282, pp.259-70, 2015.

Y. Inoue, K. Shirasuna, H. Kimura, F. Usui, A. Kawashima et al., NLRP3 regulates neutrophil functions and contributes to hepatic ischemiareperfusion injury independently of inflammasomes, J Immunol, vol.192, pp.4342-51, 2014.

A. Sadatomo, Y. Inoue, H. Ito, T. Karasawa, H. Kimura et al., Interaction of neutrophils with macrophages promotes IL-1? maturation and contributes to hepatic ischemia-reperfusion injury, J Immunol, vol.199, pp.3306-3321, 2017.

H. O. Yazdani, H. Chen, S. Tohme, S. Tai, D. J. Van-der-windt et al., IL-33 exacerbates liver sterile inflammation by amplifying neutrophil extracellular trap formation, J Hepatol, vol.68, pp.130-139, 2017.

P. Arrenberg, I. Maricic, and V. Kumar, Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice, Gastroenterology, vol.140, pp.646-55, 2011.

N. Sakai, H. L. Van-sweringen, R. M. Belizaire, R. C. Quillin, R. Schuster et al., Interleukin-37 reduces liver inflammatory injury via effects on hepatocytes and non-parenchymal cells, J Gastroenterol Hepatol, vol.27, pp.1609-1625, 2012.

Y. Muto, K. T. Nouri-aria, A. Meager, G. J. Alexander, A. L. Eddleston et al., Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure, Lancet, vol.2, pp.90006-90008, 1988.

K. D. Sekiyama, M. Yoshiba, and A. W. Thomson, Circulating proinflammatory cytokines (IL-1 beta, TNF-alpha, and IL-6) and IL-1 receptor antagonist (IL-1Ra) in fulminant hepatic failure and acute hepatitis, Clin Exp Immunol, vol.98, pp.71-78, 1994.

G. A. Roth, P. Faybik, H. Hetz, S. Hacker, H. J. Ankersmit et al., Proinflammatory interleukin-18 and Caspase-1 serum levels in liver failure are unaffected by MARS treatment, Dig Liver Dis, vol.41, pp.417-440, 2009.

G. A. Roth, M. Zimmermann, B. A. Lubsczyk, J. Pilz, P. Faybik et al., Upregulation of interleukin 33 and soluble ST2 serum levels in liver failure, J Surg Res, vol.163, pp.79-83, 2010.

J. Kim, D. Chang, H. W. Lee, H. Lee, J. H. Kim et al., Innatelike cytotoxic function of bystander-activated CD8+ T cells is associated with liver injury in acute hepatitis A, Immunity, vol.48, pp.161-73, 2018.

A. Iracheta-vellve, J. Petrasek, A. Satishchandran, B. Gyongyosi, B. Saha et al., Inhibition of sterile danger signals, uric acid and ATP, prevents inflammasome activation and protects from alcoholic steatohepatitis in mice, J Hepatol, vol.63, pp.1147-55, 2015.

J. Petrasek, S. Bala, T. Csak, D. Lippai, K. Kodys et al., IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice, J Clin Invest, vol.122, pp.3476-89, 2012.

K. Cui, G. Yan, C. Xu, Y. Chen, J. Wang et al., Invariant NKT cells promote alcohol-induced steatohepatitis through interleukin-1? in mice, J Hepatol, vol.62, pp.1311-1319, 2015.

M. J. Heo, T. H. Kim, J. S. You, D. Blaya, P. Sancho-bru et al., Alcohol dysregulates miR-148a in hepatocytes through FoxO1, facilitating pyroptosis via TXNIP overexpression, Gut, vol.68, pp.708-728, 2019.

Z. Sun, B. Chang, A. Huang, S. Hao, M. Gao et al., Plasma levels of soluble ST2, but not IL-33, correlate with the severity of alcoholic liver disease, J Cell Mol Med, vol.23, pp.887-97, 2018.

M. Wang, G. Shen, L. Xu, X. Liu, J. M. Brown et al., IL-1 receptor like 1 protects against alcoholic liver injury by limiting NF-?B activation in hepatic macrophages, J Hepatol, vol.68, pp.109-126, 2018.

I. Maricic, H. Sheng, I. Marrero, E. Seki, T. Kisseleva et al., Inhibition of type I natural killer T cells by retinoids or following sulfatidemediated activation of type II natural killer T cells attenuates alcoholic liver disease in mice, Hepatology, vol.61, pp.1357-69, 2015.

S. Mathews, D. Feng, I. Maricic, C. Ju, V. Kumar et al., Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration, Cell Mol Immunol, vol.13, pp.206-222, 2016.

E. Bugianesi, C. Rosso, and H. Cortez-pinto, How to diagnose NAFLD in 2016, J Hepatol, vol.65, pp.643-647, 2016.

S. Bellentani, The epidemiology of non-alcoholic fatty liver disease, Liver Int, vol.37, pp.81-85, 2017.

, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, European Association for the Study of the Liver (EASL), vol.59, pp.1121-1161, 2016.

J. Yu, S. Marsh, J. Hu, W. Feng, and C. Wu, The pathogenesis of nonalcoholic fatty liver disease: interplay between diet, gut microbiota, and genetic background, Gastroenterol Res Pract, p.2862173, 2016.

K. A. Negrin, R. Flach, M. T. Distefano, A. Matevossian, R. H. Friedline et al., IL-1 Signaling in obesity-induced hepatic lipogenesis and steatosis, PLoS ONE, vol.9, p.107265, 2014.

K. Miura, L. Yang, N. Van-rooijen, D. A. Brenner, H. Ohnishi et al., Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice, Hepatology, vol.57, pp.577-89, 2013.

T. Csak, M. Ganz, J. Pespisa, K. Kodys, A. Dolganiuc et al., Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells, Hepatology, vol.54, pp.133-177, 2011.

A. R. Moschen, C. Molnar, B. Enrich, S. Geiger, C. F. Ebenbichler et al., Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss, Mol Med Camb Mass, vol.17, pp.840-845, 2011.

A. L. Patrick, J. Rullo, S. Beaudin, P. Liaw, and A. E. Fox-robichaud, Hepatic leukocyte recruitment in response to time-limited expression of TNF-? and IL-1?, Am J Physiol-Gastrointest Liver Physiol, vol.293, pp.663-72, 2007.

H. Tilg, A. R. Moschen, and G. Szabo, Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, Hepatology, vol.64, pp.955-65, 2016.

Y. Kamari, A. Shaish, E. Vax, S. Shemesh, M. Kandel-kfir et al., Lack of interleukin-1? or interleukin-1? inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice, J Hepatol, vol.55, pp.1086-94, 2011.

J. Jager, T. Grémeaux, M. Cormont, L. Marchand-brustel, Y. Tanti et al., Interleukin-1?-induced insulin resistance in adipocytes through downregulation of insulin receptor substrate-1 expression, Endocrinology, vol.148, pp.241-51, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00139856

O. Nov, A. Kohl, E. C. Lewis, N. Bashan, I. Dvir et al., Interleukin-1beta may mediate insulin resistance in liver-derived cells in response to adipocyte inflammation, Endocrinology, vol.151, pp.4247-56, 2010.

H. Wen, D. Gris, Y. Lei, S. Jha, L. Zhang et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat Immunol, vol.12, pp.408-423, 2011.

T. Matsuki, R. Horai, K. Sudo, and Y. Iwakura, IL-1 plays an important role in lipid metabolism by regulating insulin levels under physiological conditions, J Exp Med, vol.198, pp.877-88, 2003.

K. Isoda, S. Sawada, M. Ayaori, T. Matsuki, R. Horai et al., Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice, J Biol Chem, vol.280, pp.7002-7011, 2005.

J. Henao-mejia, E. Elinav, J. C. Hao, L. Mehal, W. Z. Strowig et al., Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity, Nature, vol.482, pp.179-85, 2012.

P. Vasseur, S. Dion, A. Filliol, V. Genet, G. Jean-philippe et al., Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis, Oncotarget, vol.8, pp.48563-74, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01578584

Y. Gao, Y. Liu, M. Yang, X. Guo, M. Zhang et al., IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis, Oncotarget, vol.7, pp.1-13, 2016.

I. Jeftic, N. Jovicic, J. Pantic, N. Arsenijevic, M. L. Lukic et al., Galectin-3 ablation enhances liver steatosis, but attenuates inflammation and IL-33-dependent fibrosis in obesogenic mouse model of nonalcoholic steatohepatitis, Mol Med Camb Mass, vol.21, pp.453-65, 2015.

B. Jaruga, F. Hong, R. Sun, S. Radaeva, and B. Gao, Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes, J Immunol, vol.171, pp.3233-3277, 2003.

Y. Tagawa, K. Sekikawa, and Y. Iwakura, Suppression of concanavalin Ainduced hepatitis in IFN-gamma(-/-) mice, but not in TNF-alpha(-/-) mice: role for IFN-gamma in activating apoptosis of hepatocytes, J Immunol, vol.159, pp.1418-1446, 1997.

R. Zhu, S. Diem, L. M. Araujo, A. Aumeunier, J. Denizeau et al., The Pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis, J Immunol, vol.178, pp.5435-5477, 2007.
URL : https://hal.archives-ouvertes.fr/inserm-00314236

K. Takeda, Y. Hayakawa, L. Van-kaer, H. Matsuda, H. Yagita et al., Critical contribution of liver natural killer T cells to a murine model of hepatitis, Proc Natl Acad Sci, vol.97, pp.5498-503, 2000.

M. I. Arshad, C. Piquet-pellorce, L. 'helgoualc'h, A. Rauch, M. Patrat-delon et al., TRAIL but not FasL and TNF?, regulates IL-33 expression in murine hepatocytes during acute hepatitis, Hepatology, vol.56, pp.2353-62, 2012.

J. Schümann, D. Wolf, A. Pahl, K. Brune, T. Papadopoulos et al., Importance of Kupffer cells for T-cell-dependent liver injury in mice, Am J Pathol, vol.157, issue.10, pp.64804-64807, 2000.

J. Luan, X. Zhang, S. Wang, Y. Li, J. Fan et al., NOD-like receptor protein 3 inflammasome-dependent IL-1? accelerated ConA-induced Hepatitis, Front Immunol, vol.9, p.758, 2018.

G. Noel, M. I. Arshad, A. Filliol, V. Genet, M. Rauch et al., Ablation of interaction between IL-33 and ST2+ regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration, Am J Physiol Gastrointest Liver Physiol, vol.311, pp.313-336, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01366372

V. Volarevic, M. Mitrovic, M. Milovanovic, I. Zelen, I. Nikolic et al., Protective role of IL-33/ST2 axis in Con A-induced hepatitis, J Hepatol, vol.56, pp.26-33, 2012.

D. Burzyn, W. Kuswanto, D. Kolodin, J. L. Shadrach, M. Cerletti et al., A special population of regulatory T cells potentiates muscle repair, Cell, vol.155, pp.1282-95, 2013.

S. Shrivastava, A. Mukherjee, R. Ray, and R. B. Ray, Hepatitis C virus induces interleukin-1 (IL-1 )/IL-18 in circulatory and resident liver macrophages, J Virol, vol.87, pp.12284-90, 2013.

A. A. Negash, H. J. Ramos, N. Crochet, D. Lau, B. Doehle et al., IL-1? production through the NLRP3 Inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease, PLoS Pathog, vol.9, pp.1-13, 2013.

K. Yanagisawa, S. Yue, H. J. Van-der-vliet, R. Wang, N. Alatrakchi et al., Ex vivo analysis of resident hepatic pro-inflammatory CD1d-reactive T cells and hepatocyte surface CD1d expression in hepatitis C, J Viral Hepat, vol.20, pp.556-65, 2013.

P. Fisicaro, C. Valdatta, M. Massari, E. Loggi, E. Biasini et al., Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B, Gastroenterology, vol.138, pp.1-4, 2010.

M. Hofmann and R. Thimme, iNKT cells in chronic HBV: a balancing act, Hepatol Int, vol.10, pp.535-542, 2016.

M. Li, Z. Zhou, X. Sun, X. Zhang, X. Zhu et al., The dynamic changes of circulating invariant natural killer T cells during chronic hepatitis B virus infection, Hepatol Int, vol.10, pp.594-601, 2016.

K. Kimura, K. Kakimi, S. Wieland, L. G. Guidotti, and F. V. Chisari, Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice, J Virol, vol.76, pp.10702-10709, 2002.

X. X. Du, Y. Shi, Y. Yang, Y. Yu, H. G. Lou et al., DAMP molecular IL-33 augments monocytic inflammatory storm in hepatitis B-precipitated acuteon-chronic liver failure, Liver Int, vol.38, pp.229-267, 2018.

S. Huan, J. Zhao, Z. Wang, S. Gao, and K. Wang, Relevance of serum interleukin-33 and ST2 levels and the natural course of chronic hepatitis B virus infection, BMC Infect Dis, vol.16, p.200, 2016.

J. Wang, P. Zhao, H. Guo, X. Sun, Z. Jiang et al., Serum IL-33 levels are associated with liver damage in patients with chronic hepatitis C, Mediators Inflamm, p.819636, 2012.

R. G. Gieling, K. Wallace, and Y. Han, Interleukin-1 participates in the progression from liver injury to fibrosis, Am J Physiol-Gastrointest Liver Physiol, vol.296, pp.1324-1355, 2009.

P. Marvie, M. Lisbonne, L. 'helgoualc'h, A. Rauch, M. Turlin et al., Interleukin-33 overexpression is associated with liver fibrosis in mice and humans, J Cell Mol Med, vol.14, pp.1726-1765, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00660257

T. Mchedlidze, M. Waldner, S. Zopf, J. Walker, A. L. Rankin et al., Interleukin-33-dependent innate lymphoid cells mediate hepatic fibrosis, Immunity, vol.39, pp.357-71, 2013.

C. Ma, M. Han, B. Heinrich, Q. Fu, Q. Zhang et al., Gut microbiomemediated bile acid metabolism regulates liver cancer via NKT cells, Science, vol.360, p.5931, 2018.

T. Miyagi, T. Takehara, T. Tatsumi, T. Kanto, T. Suzuki et al., CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver, Int J Cancer, vol.106, pp.81-90, 2003.

M. C. Leite-de-moraes, A. Hameg, A. Arnould, F. Machavoine, Y. Koezuka et al., A distinct IL-18-induced pathway to fully activate NK T lymphocytes independently from TCR engagement, J Immunol, vol.163, pp.5871-5877, 1999.

G. Bricard, V. Cesson, E. Devevre, H. Bouzourene, C. Barbey et al., Enrichment of human CD4 + V?24/V?11 invariant NKT cells in intrahepatic malignant tumors, J Immunol, vol.182, pp.5140-51, 2009.

X. Gao, X. Wang, Q. Yang, X. Zhao, W. Wen et al., Tumoral expression of IL-33 inhibits tumor growth and modifies the tumor microenvironment through CD8 + T and NK cells, J Immunol, vol.194, pp.438-483, 2015.

C. Hollande, J. Boussier, J. Ziai, T. Nozawa, V. Bondet et al., Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL-33-dependent eosinophil-mediated control of tumor growth, Nat Immunol, vol.20, pp.257-64, 2019.
URL : https://hal.archives-ouvertes.fr/pasteur-02063831

D. O. Villarreal, M. C. Wise, J. N. Walters, E. L. Reuschel, M. J. Choi et al., Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific tumor immunity, Cancer Res, vol.74, pp.1789-800, 2014.

J. Zhang, Q. Zhang, Y. Lou, Q. Fu, Q. Chen et al., Hypoxia-inducible factor-1?/interleukin-1? signaling enhances hepatoma epithelialmesenchymal transition through macrophages in a hypoxic-inflammatory microenvironment, Hepatology, vol.67, pp.1872-89, 2018.

J. Zhao, Q. Pan, K. Pan, D. Weng, Q. Wang et al., Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: role for CD57+ NK cells, Sci Rep, vol.4, p.5177, 2015.

R. Liu, C. Tang, A. Shen, H. Luo, X. Wei et al., IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling, Oncotarget, vol.7, pp.85079-96, 2016.

T. Li, D. Zhu, T. Mou, Z. Guo, J. Pu et al., IL-37 induces autophagy in hepatocellular carcinoma cells by inhibiting the PI3K/AKT/mTOR pathway, Mol Immunol, vol.87, pp.132-172, 2017.

Y. Yang, J. B. Wang, Y. M. Li, Y. Zhao, R. Wang et al., Role of IL-33 expression in oncogenesis and development of human hepatocellular carcinoma, Oncol Lett, vol.12, pp.429-465, 2016.

P. Zhang, X. Liu, Z. Chu, J. Ye, K. Li et al., Detection of interleukin-33 in serum and carcinoma tissue from patients with hepatocellular carcinoma and its clinical implications, J Int Med Res, vol.40, pp.1654-61, 2012.

D. Bergis, V. Kassis, A. Ranglack, V. Koeberle, A. Piiper et al., High serum levels of the interleukin-33 receptor soluble ST2 as a negative prognostic factor in hepatocellular carcinoma, Transl Oncol, vol.6, pp.311-319, 2013.

C. Berasain, J. Castillo, M. J. Perugorria, M. U. Latasa, J. Prieto et al., Inflammation and liver cancer: new molecular links, Ann N Y Acad Sci, vol.1155, pp.206-227, 2009.

X. Wu, L. Dong, X. Lin, and J. Li, Relevance of the NLRP3 inflammasome in the pathogenesis of chronic liver disease. Front Immunol, vol.8, p.1728, 2017.

Y. Yang, H. Wang, M. Kouadir, H. Song, and F. Shi, Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors, Cell Death Dis, vol.10, p.128, 2019.

A. M. Adkison, S. Z. Raptis, D. G. Kelley, and C. Pham, Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis, J Clin Invest, vol.109, pp.363-71, 2002.

J. A. Lust, M. Q. Lacy, S. R. Zeldenrust, T. E. Witzig, L. L. Moon-tasson et al., Reduction in C-reactive protein indicates successful targeting of the IL-1/IL-6 axis resulting in improved survival in early stage multiple myeloma, Am J Hematol, vol.91, pp.571-575, 2016.

T. Wu, K. Xu, J. Martinek, R. R. Young, R. Banchereau et al., IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer, Cancer Res, vol.78, pp.5243-58, 2018.

P. M. Ridker, B. M. Everett, T. Thuren, J. G. Macfadyen, W. H. Chang et al., Antiinflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med, vol.377, pp.1119-1150, 2017.

M. E. Stremska, S. Jose, V. Sabapathy, L. Huang, A. Bajwa et al., A novel IL-2 and IL-33 hybrid cytokine, ameliorates renal injury, J Am Soc